Insider Buying: Second Sight Medical Products Inc (EYES) Director Buys 2,467,767 Shares of Stock

Second Sight Medical Products Inc (NASDAQ:EYES) Director Gregg Williams acquired 2,467,767 shares of Second Sight Medical Products stock in a transaction on Thursday, October 18th. The shares were purchased at an average price of $1.62 per share, for a total transaction of $3,997,782.54. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Gregg Williams also recently made the following trade(s):

  • On Monday, October 15th, Gregg Williams acquired 7,645 shares of Second Sight Medical Products stock. The shares were purchased at an average price of $1.63 per share, for a total transaction of $12,461.35.
  • On Thursday, October 11th, Gregg Williams acquired 11,709 shares of Second Sight Medical Products stock. The shares were purchased at an average price of $1.60 per share, for a total transaction of $18,734.40.
  • On Tuesday, October 9th, Gregg Williams acquired 10,458 shares of Second Sight Medical Products stock. The shares were purchased at an average price of $1.64 per share, for a total transaction of $17,151.12.
  • On Friday, October 5th, Gregg Williams acquired 15,875 shares of Second Sight Medical Products stock. The shares were purchased at an average price of $1.72 per share, for a total transaction of $27,305.00.
  • On Wednesday, October 3rd, Gregg Williams acquired 24,075 shares of Second Sight Medical Products stock. The shares were purchased at an average price of $1.79 per share, for a total transaction of $43,094.25.
  • On Friday, September 28th, Gregg Williams acquired 9,223 shares of Second Sight Medical Products stock. The shares were purchased at an average price of $1.90 per share, for a total transaction of $17,523.70.
  • On Monday, October 1st, Gregg Williams acquired 25,098 shares of Second Sight Medical Products stock. The shares were purchased at an average price of $1.88 per share, for a total transaction of $47,184.24.
  • On Wednesday, September 26th, Gregg Williams acquired 10,878 shares of Second Sight Medical Products stock. The shares were purchased at an average price of $1.96 per share, for a total transaction of $21,320.88.
  • On Monday, September 24th, Gregg Williams acquired 15,520 shares of Second Sight Medical Products stock. The shares were purchased at an average price of $1.86 per share, for a total transaction of $28,867.20.
  • On Friday, September 21st, Gregg Williams acquired 15,875 shares of Second Sight Medical Products stock. The shares were purchased at an average price of $1.80 per share, for a total transaction of $28,575.00.

Shares of NASDAQ:EYES traded up $0.03 on Monday, reaching $1.60. The company had a trading volume of 167,362 shares, compared to its average volume of 206,057. Second Sight Medical Products Inc has a 52-week low of $1.05 and a 52-week high of $2.58. The company has a market capitalization of $105.31 million, a PE ratio of -2.71 and a beta of 3.07.

Second Sight Medical Products (NASDAQ:EYES) last announced its quarterly earnings results on Tuesday, August 7th. The medical device company reported ($0.12) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.14) by $0.02. Second Sight Medical Products had a negative return on equity of 432.45% and a negative net margin of 418.82%. The business had revenue of $1.91 million for the quarter, compared to the consensus estimate of $2.21 million. Sell-side analysts forecast that Second Sight Medical Products Inc will post -0.58 EPS for the current fiscal year.

EYES has been the topic of several research reports. Zacks Investment Research upgraded Second Sight Medical Products from a “sell” rating to a “hold” rating in a report on Monday, September 24th. HC Wainwright set a $5.00 price objective on Second Sight Medical Products and gave the stock a “buy” rating in a report on Wednesday, August 8th.

Second Sight Medical Products Company Profile

Second Sight Medical Products, Inc develops, manufactures and markets prosthetic devices. Its product the Argus II System, treats outer retinal degenerations and employs electrical stimulation to bypass degenerated photoreceptor cells and to stimulate remaining viable retinal cells thereby inducing visual perception in blind individuals.

Further Reading: Trading Strategy Examples and Plans

Insider Buying and Selling by Quarter for Second Sight Medical Products (NASDAQ:EYES)

Receive News & Ratings for Second Sight Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply